PAVM Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of 14.61%. PAVmed, Inc.'s return on equity of 8.75% beat Electromed, Inc.'s return on equity of 20.35%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2624.67%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 42.52%. Given that PAVmed, Inc. has higher upside potential than Electromed, Inc., analysts believe PAVmed, Inc. is more attractive than Electromed, Inc..

PAVmed, Inc. has a beta of 1.118, which suggesting that the stock is 11.802% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.264, suggesting its less volatile than the S&P 500 by 73.581%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Electromed, Inc. quarterly revenues of $18.9M. PAVmed, Inc.'s net income of -$6M is lower than Electromed, Inc.'s net income of $2.8M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Electromed, Inc.'s PE ratio is 24.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 4,886.53x versus 3.22x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Escalon Medical Corp. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -8.97%. PAVmed, Inc.'s return on equity of 8.75% beat Escalon Medical Corp.'s return on equity of -5.28%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2624.67%. On the other hand Escalon Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 7172.73%. Given that Escalon Medical Corp. has higher upside potential than PAVmed, Inc., analysts believe Escalon Medical Corp. is more attractive than PAVmed, Inc..

PAVmed, Inc. has a beta of 1.118, which suggesting that the stock is 11.802% more volatile than S&P 500. In comparison Escalon Medical Corp. has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.1%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Escalon Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Escalon Medical Corp. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Escalon Medical Corp. quarterly revenues of $2.7M. PAVmed, Inc.'s net income of -$6M is lower than Escalon Medical Corp.'s net income of -$239.9K. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Escalon Medical Corp.'s PE ratio is 154.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 4,886.53x versus 0.15x for Escalon Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -12.6%. PAVmed, Inc.'s return on equity of 8.75% beat IRIDEX Corp.'s return on equity of -155.93%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2624.67%. On the other hand IRIDEX Corp. has an analysts' consensus of $3.00 which suggests that it could grow by 109.79%. Given that PAVmed, Inc. has higher upside potential than IRIDEX Corp., analysts believe PAVmed, Inc. is more attractive than IRIDEX Corp..

PAVmed, Inc. has a beta of 1.118, which suggesting that the stock is 11.802% more volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.514%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than IRIDEX Corp. quarterly revenues of $12.5M. PAVmed, Inc.'s net income of -$6M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 4,886.53x versus 0.47x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.